pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›COMETRIQ
drug · small molecule
save

COMETRIQ

updated 3mo ago
by $EXEL EXELIXIS, INC.🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 8
  • drugcabozantinib s-malate97 co-mentions · 25 sources
  • drugCABOMETYX97 co-mentions · 25 sources
  • tagApproval96 co-mentions · 24 sources
  • tagSmall Molecule48 co-mentions · 24 sources
  • drugcabozantinib48 co-mentions · 24 sources
  • tagOncology2 co-mentions · 1 sources
  • company$TAKTAKEDA PHARMACEUTICAL CO LTD1 co-mentions · 1 sources
  • company$TKPHFTAKEDA PHARMACEUTICAL CO LTD1 co-mentions · 1 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 9 investigational indications.

targets

Hepatocyte growth factor receptorVascular endothelial growth factor receptor 2

all catalysts(0)

nothing on the calendar yet

Trials studying COMETRIQ

  • phase1Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancerrecruitingn=32
  • phase2Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremitiesterminatedn=6

News(0)

no news has mentioned this drug yet

brand
COMETRIQ
trade names
Cabometyx, Cometriq
generic
CABOZANTINIB S-MALATE
MOA
12.1 Mechanism of Action In vitro biochemical and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of RET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, ROS1, TYRO3, MER, and TIE-2. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, drug resistance, and maintenance of the tumor microenvironment.
indication
1 INDICATIONS AND USAGE COMETRIQ is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). COMETRIQ is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). ( 1 )
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?